On June 3, 2026, Beijing Shougang Langze Technology Co., Ltd. ("Shougang Langze," stock code: $SHOUGANG LANZA (02553.HK)$ ) officially listed on the Main Board of the Hong Kong Stock Exchange, marking the company's official entry into a new phase of development driven by a global capital platform.
In this global offering, Futu acted as joint bookrunner and joint lead manager, partnering with Yuexiu Capital, Yuexiu Securities, Mango Finance, CCB International, and Minsheng Capital, among other institutions, to form a robust underwriting syndicate. Leveraging its advanced trading platform and diverse investor ecosystem, Futu played a pivotal role in matching the company with a vast pool of institutional and retail investors, thereby strengthening its global investor base and enhancing secondary market liquidity.
According to the prospectus and related announcements, the global offering comprised 40 million H-shares, priced at HK$14.60 per share, raising net proceeds of approximately HK$486 million. No cornerstone investor allocation was disclosed for this IPO, while the international tranche attracted subscriptions from 97 professional institutional and individual investors, underscoring strong global investor confidence in the synthetic biology CCUS sector and the company’s industrial capabilities.
According to Frost & Sullivan data, based on 2025 revenue, Shougang Langze holds a 58.4% market share globally in the synthetic biology-based CCUS segment...
In this global offering, Futu acted as joint bookrunner and joint lead manager, partnering with Yuexiu Capital, Yuexiu Securities, Mango Finance, CCB International, and Minsheng Capital, among other institutions, to form a robust underwriting syndicate. Leveraging its advanced trading platform and diverse investor ecosystem, Futu played a pivotal role in matching the company with a vast pool of institutional and retail investors, thereby strengthening its global investor base and enhancing secondary market liquidity.
According to the prospectus and related announcements, the global offering comprised 40 million H-shares, priced at HK$14.60 per share, raising net proceeds of approximately HK$486 million. No cornerstone investor allocation was disclosed for this IPO, while the international tranche attracted subscriptions from 97 professional institutional and individual investors, underscoring strong global investor confidence in the synthetic biology CCUS sector and the company’s industrial capabilities.
According to Frost & Sullivan data, based on 2025 revenue, Shougang Langze holds a 58.4% market share globally in the synthetic biology-based CCUS segment...
+1
1
May 27, 2026,the first AI agent for enterprise decision-making—Beijing DeepAI Intelligence Technology Co., Ltd. (short name: DeepAI Intelligence, stock code: $DEEPZERO (02723.HK)$ ) has successfully listed on the Main Board of the Hong Kong Stock Exchange, officially becoming the first AI agent for enterprise decision-making and entering a new phase of capital market development.
In this IPO process, Futu participated throughout the offering as a joint bookrunner (JBR) and joint lead manager (JLM). Leveraging its global technology trading platform advantages and extensive network of high-net-worth and institutional investors, Futu efficiently introduced diversified, high-quality, and actively trading global capital to DeepAI Intelligence, strengthening the company's investor base and laying a solid foundation for post-listing stock activity and market liquidity.
In addition,Futu provided media outreach services for DeepAI Intelligence, helping it build communication bridges with all participants in the Hong Kong capital market and convey the company's value.
According to the prospectus, DeepAI Intelligence is a leading provider of AI applications for marketing and sales decision-making in China, offering a comprehensive product portfolio comprising 'intelligent ad buying, intelligent data management, and enterprise AI agents,' with core products including the AlphaDesk, AlphaData, and DeepAgent series. According to Frost & Sullivan:
– Ranked by revenue in 2024, the company is among the top players in China’s marketing and sales decision-making AI application market...
In this IPO process, Futu participated throughout the offering as a joint bookrunner (JBR) and joint lead manager (JLM). Leveraging its global technology trading platform advantages and extensive network of high-net-worth and institutional investors, Futu efficiently introduced diversified, high-quality, and actively trading global capital to DeepAI Intelligence, strengthening the company's investor base and laying a solid foundation for post-listing stock activity and market liquidity.
In addition,Futu provided media outreach services for DeepAI Intelligence, helping it build communication bridges with all participants in the Hong Kong capital market and convey the company's value.
According to the prospectus, DeepAI Intelligence is a leading provider of AI applications for marketing and sales decision-making in China, offering a comprehensive product portfolio comprising 'intelligent ad buying, intelligent data management, and enterprise AI agents,' with core products including the AlphaDesk, AlphaData, and DeepAgent series. According to Frost & Sullivan:
– Ranked by revenue in 2024, the company is among the top players in China’s marketing and sales decision-making AI application market...
1
2
On May 20, 2026, Yushi Technology (Beijing) Co., Ltd. (“Yushi Technology,” stock code: $UISEE TECH (01511.HK)$ ), a leading provider of Level 4 autonomous driving solutions, officially listed on the Main Board of the Hong Kong Stock Exchange, marking its entry into international capital markets and launching a new phase of growth.
In this global offering, Futu acted as joint bookrunners and joint lead managers, partnering with prominent institutions including CITIC Securities, Bank of Communications International, DBS, and China Galaxy International to form a strong underwriting syndicate. Leveraging its technology-driven trading platform and diversified investor ecosystem, Futu helped Uisee Technology precisely connect with global investors and solidify the liquidity foundation in the secondary market.
According to the prospectus, the IPO secured cornerstone investments from Xiong’an Autonomous Driving Co., Ltd., CYGG Holding Limited (a wholly owned subsidiary of 58 Group), and Starwin International, which collectively subscribed for approximately HK$261 million, representing 29.96% of the total global offering shares (assuming the over-allotment option is not exercised), reflecting investors’ confidence in the company’s long-term growth potential.
According to Frost & Sullivan, Uisee Technology is the only company globally capable of providing large-scale commercial L4 autonomous driving solutions for airports. In 2025, it held a 90.5% market share in the Greater China region for L4 commercial vehicles deployed in airport scenarios, ...
In this global offering, Futu acted as joint bookrunners and joint lead managers, partnering with prominent institutions including CITIC Securities, Bank of Communications International, DBS, and China Galaxy International to form a strong underwriting syndicate. Leveraging its technology-driven trading platform and diversified investor ecosystem, Futu helped Uisee Technology precisely connect with global investors and solidify the liquidity foundation in the secondary market.
According to the prospectus, the IPO secured cornerstone investments from Xiong’an Autonomous Driving Co., Ltd., CYGG Holding Limited (a wholly owned subsidiary of 58 Group), and Starwin International, which collectively subscribed for approximately HK$261 million, representing 29.96% of the total global offering shares (assuming the over-allotment option is not exercised), reflecting investors’ confidence in the company’s long-term growth potential.
According to Frost & Sullivan, Uisee Technology is the only company globally capable of providing large-scale commercial L4 autonomous driving solutions for airports. In 2025, it held a 90.5% market share in the Greater China region for L4 commercial vehicles deployed in airport scenarios, ...
On May 13, 2026, $METIS TECHBIO-P (07666.HK)$ officially listed on the main board of the Hong Kong Exchange, becoming the First AI Drug Delivery Stock, and another hardcore biotech company listed under Chapter 18C of the Hong Kong Exchange.In this IPO, Futu served as the joint bookrunner and joint lead manager, leveraging the core advantages of its technology-empowered platform ecosystem to precisely cover a large number of high-quality investors during the public offering phase, laying a solid foundation for JiTai Technology's secondary market liquidity and trading activity post-listing.
The cornerstone investor lineup for this IPO is considered top-tier, featuring 18 global leading institutions including Blackrock, UBS AM Singapore, China Venture Capital Innovation Investment Fund, Mirae Asset, Hillhouse HHLRA, Deerfield, and RTW funds. Together, they subscribed for $148 million (approximately HK$1.159 billion), accounting for 54.87% of the offered shares. This sets a new record for cornerstone investments in the AI pharmaceuticals sector in Hong Kong stocks, fully demonstrating the international capital market’s high recognition of JiTai Technology’s technical capabilities and development prospects.
JiTai Technology is an AI-driven biotech company focused on the development and technological innovation of materials for drug nanodelivery. The company independently developed NanoForge, the world’s first AI-driven drug nanodelivery platform. NanoForge can reduce the formulation research and development time for small molecule drugs from...
The cornerstone investor lineup for this IPO is considered top-tier, featuring 18 global leading institutions including Blackrock, UBS AM Singapore, China Venture Capital Innovation Investment Fund, Mirae Asset, Hillhouse HHLRA, Deerfield, and RTW funds. Together, they subscribed for $148 million (approximately HK$1.159 billion), accounting for 54.87% of the offered shares. This sets a new record for cornerstone investments in the AI pharmaceuticals sector in Hong Kong stocks, fully demonstrating the international capital market’s high recognition of JiTai Technology’s technical capabilities and development prospects.
JiTai Technology is an AI-driven biotech company focused on the development and technological innovation of materials for drug nanodelivery. The company independently developed NanoForge, the world’s first AI-driven drug nanodelivery platform. NanoForge can reduce the formulation research and development time for small molecule drugs from...
1
On May 11, 2026, Shenzhen Ledong Robotics Co., Ltd. (referred to as 'Ledong Robotics', stock code: $LDROBOT (01236.HK)$ ) officially listed on the Main Board of the Hong Kong Stock Exchange, marking the company's official entry into a new phase of development driven by a global capital platform.
In this global offering, Futu Securities acted as joint bookrunners and joint lead managers, forming part of the underwriting syndicate alongside Haitong International and Guotai Junan International, leveraging the advantages of a technology trading platform to help the company attract a diverse range of investors and build a solid foundation for subsequent market liquidity. Additionally, Futu Finance provided LD Robot with one-stop financial advisory services including IPO communications, media outreach, listing ceremony coordination, and thank-you dinner planning, helping it establish communication channels with participants in the Hong Kong capital market and communicate the company’s value.
According to the prospectus disclosure, this IPO introduced Chengtong Hengyuan Investment Co., Ltd. as a cornerstone investor, subscribing to approximatelyHK$277 million, accounting for30.78%of the total number of shares offered globally at the mid-point of the offering price, demonstrating the capital market's recognition of the company's technological barriers and growth potential.
According to CIC data, based on revenue in 2024, LD Robot ranked first globallyin the market share for intelligent robot vision perception solutions; equipped with...
In this global offering, Futu Securities acted as joint bookrunners and joint lead managers, forming part of the underwriting syndicate alongside Haitong International and Guotai Junan International, leveraging the advantages of a technology trading platform to help the company attract a diverse range of investors and build a solid foundation for subsequent market liquidity. Additionally, Futu Finance provided LD Robot with one-stop financial advisory services including IPO communications, media outreach, listing ceremony coordination, and thank-you dinner planning, helping it establish communication channels with participants in the Hong Kong capital market and communicate the company’s value.
According to the prospectus disclosure, this IPO introduced Chengtong Hengyuan Investment Co., Ltd. as a cornerstone investor, subscribing to approximatelyHK$277 million, accounting for30.78%of the total number of shares offered globally at the mid-point of the offering price, demonstrating the capital market's recognition of the company's technological barriers and growth potential.
According to CIC data, based on revenue in 2024, LD Robot ranked first globallyin the market share for intelligent robot vision perception solutions; equipped with...
On May 6, 2026, $COFOE MEDICAL (01187.HK)$ officially listed on the Main Board of the Hong Kong Stock Exchange, becomingthe fourth “A+H” listed company in Hunan Province.In this IPO,Futu served as the overall coordinator (OC), joint global coordinator (JGC), joint bookrunners (JBR), and joint lead manager (JLM), playing a deep role throughout the entire issuance process.
In the meantime,Futu was also the financial public relations partner for this IPO, leveraging its professional expertise and mature service system within the capital markets to empower this IPO.
Cofoe Medical is a leading domestic home medical device company in China. With a product portfolio that includes over 200 products and tens of thousands of product specifications, Cofoe Medical can effectively meet the needs of family members across different age groups. According to Frost & Sullivan, by domestic revenue in 2024, the company ranks second among all home medical device companies in China, with a market share of 2.1%.
For the fiscal years ended December 31, 2023, 2024, and 2025, Cofoe Medical's revenues were RMB 2,853.7 million, RMB 2,982.9 million, and RMB 3,387.5 million, respectively. The company’s gross profits for 2023, 2024, and 2025 were RMB 1,172.6 million, RMB 1,508.7 million...
In the meantime,Futu was also the financial public relations partner for this IPO, leveraging its professional expertise and mature service system within the capital markets to empower this IPO.
Cofoe Medical is a leading domestic home medical device company in China. With a product portfolio that includes over 200 products and tens of thousands of product specifications, Cofoe Medical can effectively meet the needs of family members across different age groups. According to Frost & Sullivan, by domestic revenue in 2024, the company ranks second among all home medical device companies in China, with a market share of 2.1%.
For the fiscal years ended December 31, 2023, 2024, and 2025, Cofoe Medical's revenues were RMB 2,853.7 million, RMB 2,982.9 million, and RMB 3,387.5 million, respectively. The company’s gross profits for 2023, 2024, and 2025 were RMB 1,172.6 million, RMB 1,508.7 million...
2
1
May 5, 2026, $STAR SPORTS MED (01609.HK)$successfully listed on the Main Board of the Hong Kong Exchange. This IPO was highly sought after by the market, with the public offering being oversubscribed by 7,823.13 times, demonstrating strong recognition from the capital markets of the company’s long-term value.Futu served as the joint global coordinator, joint bookrunners, and joint lead manager for this IPO, leveraging the advantages of its technology-driven trading platform to precisely reach a large number of high-quality investors during the public offering phase, laying a solid foundation for Tianxing Medical’s post-listing market liquidity and trading activity.
In this IPO, Tianxing Medical introduced Beijing Finance's JSC International (representing Shenghai SP), OrbiMed's Orbimed Asia Partners IV, and Greater Bay Area Homeland Investment as cornerstone investors, with an investment amount of $37 million (approximately HK$290 million).
Tianxing Medical is a China-based medical device company focusing on clinical solutions in sports medicine. According to data from CIC Consulting, based on 2024 revenue, the company ranks as the fourth-largest provider of sports medicine implants and devices in China, holding approximately 6.5% of the domestic sports medicine implant and device market share and is also the largest domestic provider in this sector.
Financially, according to the prospectus, the company's revenue increased from RMB 238.5 million in 2023 to RMB 327.1 million in 2024...
In this IPO, Tianxing Medical introduced Beijing Finance's JSC International (representing Shenghai SP), OrbiMed's Orbimed Asia Partners IV, and Greater Bay Area Homeland Investment as cornerstone investors, with an investment amount of $37 million (approximately HK$290 million).
Tianxing Medical is a China-based medical device company focusing on clinical solutions in sports medicine. According to data from CIC Consulting, based on 2024 revenue, the company ranks as the fourth-largest provider of sports medicine implants and devices in China, holding approximately 6.5% of the domestic sports medicine implant and device market share and is also the largest domestic provider in this sector.
Financially, according to the prospectus, the company's revenue increased from RMB 238.5 million in 2023 to RMB 327.1 million in 2024...
2
On April 29, 2026, Shanghai Sunmi Technology Group Co., Ltd. (referred to as: Sunmi Technology, stock code: 6810.HK) successfully listed on the Main Board of the Hong Kong Exchange. As one of the joint bookrunners and joint lead managers of this IPO, Futu fully leveraged its technological trading platform advantages, efficiently reaching high-quality investor groups during the public offering phase, laying a solid foundation for liquidity and trading activity after Sunmi Technology’s listing.
Sunmi Technology, established in 2013, is a world-leading Business Internet of Things (BIoT) solutions provider. Its disruptive solutions integrate smart hardware, software, and data insights, empowering numerous offline commercial scenarios to achieve digital transformation and enhance core operational processes such as payment, membership management, order fulfillment, inventory control, and employee management. According to CIC data, as of 2024 by revenue, Sunmi Technology is currently the largest Android-based BIoT solutions provider globally, capturing more than 10% market share. The Android-based BIoT solutions market is expected to experience explosive growth over the next five years.
In this IPO, the company introduced cornerstone investors such as China Orient Enhanced Income Fund, collectively subscribing to approximately HKD 286 million worth of shares, accounting for about 27.03% of the offered shares. In terms of shareholders, the company has received backing from top-tier capital firms including Ant Group, Meituan, Xiaomi, Shenzhen Capital Group, Lightspeed China Partners...
Sunmi Technology, established in 2013, is a world-leading Business Internet of Things (BIoT) solutions provider. Its disruptive solutions integrate smart hardware, software, and data insights, empowering numerous offline commercial scenarios to achieve digital transformation and enhance core operational processes such as payment, membership management, order fulfillment, inventory control, and employee management. According to CIC data, as of 2024 by revenue, Sunmi Technology is currently the largest Android-based BIoT solutions provider globally, capturing more than 10% market share. The Android-based BIoT solutions market is expected to experience explosive growth over the next five years.
In this IPO, the company introduced cornerstone investors such as China Orient Enhanced Income Fund, collectively subscribing to approximately HKD 286 million worth of shares, accounting for about 27.03% of the offered shares. In terms of shareholders, the company has received backing from top-tier capital firms including Ant Group, Meituan, Xiaomi, Shenzhen Capital Group, Lightspeed China Partners...
1
1
On April 28, 2026, Mabwell (Shanghai) Biotechnology Co., Ltd. (referred to as: Mabwell Bio-B, stock code: $MABWELL-B (02493.HK)$ ) successfully went public on the Main Board of the Hong Kong Stock Exchange, officially entering a new phase of coordinated development with 'A+H' dual capital platforms.
During this IPO process, Futu Securities International (Hong Kong) Co., Ltd. acted as theJoint Global Coordinator (JGC)Participated in the entire issuance process. Leveraging the advantages of a global technology trading platform and abundant high-net-worth and institutional investor resources, Futu efficiently introduced diverse, high-quality, and actively traded global capital for Mabwell Bio, strengthening the investor base and laying a solid foundation for post-listing stock activity and market liquidity.
According to the prospectus, Mabwell Bio introducedJunshi Limited, Sanjin International Co., Ltd. (Guilin Sanjin), Guohui (Hong Kong) Holdings Limited, Changrong International Limited, Wuxi Bio Healthcare Venture, and Jinxiu Zhonghe Investmentas cornerstone investors, collectively subscribing for a total amount of approximately USD 53 million (about HKD 415 million), providing strong support for the company's long-term stable development.
The prospectus shows that Mabwell Bio is a leading innovative biopharmaceutical company in China, focusing on oncology and age-related...
During this IPO process, Futu Securities International (Hong Kong) Co., Ltd. acted as theJoint Global Coordinator (JGC)Participated in the entire issuance process. Leveraging the advantages of a global technology trading platform and abundant high-net-worth and institutional investor resources, Futu efficiently introduced diverse, high-quality, and actively traded global capital for Mabwell Bio, strengthening the investor base and laying a solid foundation for post-listing stock activity and market liquidity.
According to the prospectus, Mabwell Bio introducedJunshi Limited, Sanjin International Co., Ltd. (Guilin Sanjin), Guohui (Hong Kong) Holdings Limited, Changrong International Limited, Wuxi Bio Healthcare Venture, and Jinxiu Zhonghe Investmentas cornerstone investors, collectively subscribing for a total amount of approximately USD 53 million (about HKD 415 million), providing strong support for the company's long-term stable development.
The prospectus shows that Mabwell Bio is a leading innovative biopharmaceutical company in China, focusing on oncology and age-related...
On April 28, 2026, Shanghai XtalPi Technology Co., Ltd. (referred to as: XtalPi Technology, stock code: $XIZHI TECH-P (01879.HK)$ ), successfully listed on the Main Board of the Hong Kong Stock Exchange, becoming the 'world's first AI silicon photonics chip stock,' officially entering a new stage of global development.
In this IPO process, Futu Securities International (Hong Kong) Co., Ltd. acted as thejoint bookrunnersand participated in the entire issuance process. Relying on the advantages of its global technology trading platform and vast resources of high-net-worth and institutional investors, Futu efficiently introduced diversified, high-quality, and actively traded global capital for XtalPi Technology, helping the company solidify its investor structure and laying a solid foundation for post-listing stock activity and market liquidity.
In addition, Futu Finance provides one-stop financial advisory services for曦智科技, including IPO financial consulting, media outreach, and appreciation banquets, helping it build communication bridges with all participants in the Hong Kong capital market and convey the company's value.
According to the prospectus disclosure, XtalPi Technology's IPO introduced20 cornerstone investors, including industry giants such as Alibaba, China Mobile Capital, Lenovo, ZTE, as well as international sovereign funds and long-term capital like GIC, Blackrock, Fidelity International, and Temasek, with a total subscription amount of approximately $209.9 million (about HK$1.644 billion), accounting for the global offering shares...
In this IPO process, Futu Securities International (Hong Kong) Co., Ltd. acted as thejoint bookrunnersand participated in the entire issuance process. Relying on the advantages of its global technology trading platform and vast resources of high-net-worth and institutional investors, Futu efficiently introduced diversified, high-quality, and actively traded global capital for XtalPi Technology, helping the company solidify its investor structure and laying a solid foundation for post-listing stock activity and market liquidity.
In addition, Futu Finance provides one-stop financial advisory services for曦智科技, including IPO financial consulting, media outreach, and appreciation banquets, helping it build communication bridges with all participants in the Hong Kong capital market and convey the company's value.
According to the prospectus disclosure, XtalPi Technology's IPO introduced20 cornerstone investors, including industry giants such as Alibaba, China Mobile Capital, Lenovo, ZTE, as well as international sovereign funds and long-term capital like GIC, Blackrock, Fidelity International, and Temasek, with a total subscription amount of approximately $209.9 million (about HK$1.644 billion), accounting for the global offering shares...
3
![[empty]](https://static.futunn.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.futunn.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,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)